Kneat said the Ontario Superior Court of Justice (Commercial List) issued a final order on August 6, 2026 approving the plan of arrangement under which an affiliate of Thoma Bravo, L.P. will acquire all outstanding common shares other than rollover shares, clearing the last major court step for the take-private transaction. The arrangement agreement was signed on June 8, 2026, and the company expects the deal to close on or about August 11, 2026, subject to remaining customary conditions. Limerick, Ireland-based Kneat sells its Kneat Gx digital validation platform to pharmaceutical, biotechnology and medical device companies, with ISO 9001 and ISO 27001 certifications, compliance with 21 CFR Part 11 and Annex 11, and optional AI tools designed to speed validation workflows while preserving GxP controls. The company has a market capitalization of about C$622 million, average daily trading volume of 341,600 shares, and analysts remain cautious, with the latest rating at Hold and a C$6.50 price target.